News & Commentary

As we approach the 16-month mark since we had pivotal arguments over the 340B contract pharmacy program in two federal appellate courts and Congress continues to offer no relief, a growing number of 340B providers are turning to state legislatures … [Read more...]

Long-time 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health centers. In September, Cassidy, a long-time critic of the program, launched an inquiry into hospital use of the … [Read more...]

In what legal experts describe as a landmark decision, the U.S. District Court for the District of South Carolina ruled Nov. 3 that the plain wording of the 340B statute does not require a covered entity to have initiated a healthcare service … [Read more...]

According to our history lessons, George Washington told Thomas Jefferson that the Senate was created to serve as a saucer to “cool” the House’s hot cup of tea. … [Read more...]

After a recent lull in the ongoing battle over whether drug manufacturers can continue to place restrictions on access to 340B discounts in the contract pharmacy setting, things are heating up at the state level. … [Read more...]

As we pass the third anniversary of the pharmaceutical industry’s surprise decision to significantly scale back access to 340B pricing in the contract pharmacy setting, the key question is:  Why is it taking so long to come up with a … [Read more...]

Just before the end of most state legislative sessions for 2023, two states enacted the first ever 340B-specific reporting requirements for covered entities. As my colleague Will Newton reported in 340B Report, Minnesota was the first to enact a … [Read more...]

As many 2023 state legislative sessions come to an end, it is a good time to take a closer look at two states—one in the South and one in the Northeast—to see how they are tackling some of the most pressing matters impacting 340B stakeholders. … [Read more...]

As we reach the third-year mark since pharmaceutical manufacturers began to restrict access to 340B pricing in the contract pharmacy setting, we recently experienced a watershed moment that I believe will lead to an end of the standoff between the … [Read more...]

With the recent launch of 340B Truth and with several other advocacy/educational groups using 340B in their names, it is a good time to provide a tutorial on the different groups and their goals.  The list below is not exhaustive but reflects … [Read more...]